10840_004_header_800
Download Brochure
   
   
   
   
   
 
Email Updates
 
   
   
   
   
   

Presentations

David Kalergis, Chief Executive Officer, Diffusion Pharmaceuticals LLC

Case Study: Global Partnering Challenges: A Small Biotech’s Perspective

    

Catherine Sazdanoff, Vice President, Global Licensing, Takeda Pharmaceuticals North America

Case Study: The $8.8 Billion Acquisition of Millennium Pharmaceuticals By Japan’s Takeda

    

Anna Protopapas, Senior Vice President of Corporate Development, Millennium Pharmaceuticals

Case Study: The $8.8 Billion Acquisition of Millennium Pharmaceuticals By Japan’s Takeda

    

Reid Leonard, Vice President, External Licensing and Business Development, Merck

Case Study: Merck’s Partnerships In India

    

Stephanie Hsieh, Senior Director, Intellectual Property and Legal Affairs, Impax Laboratories

Case Study: Discussing The Competitive Advantages Of Bringing Generic Drugs Into The Branded Space

    

David Paterson PhD, Vice President, Business Development, Impax Pharmaceuticals, Inc

Case Study: Discussing The Competitive Advantages Of Bringing Generic Drugs Into The Branded Space

    

Iain Dukes, President and CEO, Essentialis

Case Study: Planning For The Big Deal: Options Analysis Ahead Of Critical Data

    

Pavan Handa, Vice President, Business Development and Alliance Management, Noven Pharmaceuticals, Inc.

Building a Profitable Product Portfolio Utilizing Innovative Drug Delivery Technologies

    

Jeffrey Totten, Vice President, Dean & Company

Chairperson’s Morning Opening Remarks

Jeffrey Totten, Vice President, Dean & Company

Chairperson’s Afternoon Opening Remarks

    

Lily Zou, Director, Business Development, ArQule, Inc.

Therapeutic Area Partnering Primers-Oncology

    

Iain Dukes, President and CEO, Essentialis

Therapeutic Area Partnering Primers- Cardiovascular

    

Vidal de la Cruz, Vice President, Business Development, Cytokine PharmaSciences, Inc.

Therapeutic Area Partnering Primers-Auto-Immune

    

Ira Weisberg, Vice President, Business Development, Lifecycle Pharma

Case Study: Successfully Negotiating Structured Royalty Agreements

    

Matt Reber, Vice President, Cowen Healthcare Royalty Partners

Case Study: Successfully Negotiating Structured Royalty Agreements

    

John M. Hession, Partner In Charge, Boston Offices, Cooley Godward Kronish LLP

Panel Discussion: Creative Exit Strategies For Biotech Companies

    

Matt Meyer, Vice President Business Development and Licensing, Cerimon

Case Study: Understanding The Unique Collaboration Between Large Pharma (Novartis) And Small Pharma (Cerimon)

    

Arne Wörn PhD, Head Alliance Management, Immunology & Infectious Diseases Business Franchise, Global Business Development & Licensing, Novartis Pharma

Case Study: Understanding The Unique Collaboration Between Large Pharma (Novartis) And Small Pharma (Cerimon)

    

Thanos Maroglou, Vice President, Business Development, Chimerix Inc.

Panel Discussion: Creative Exit Strategies For Biotech Companies

    

Stephen Potter, Senior Vice President of Corporate Business Development, Genzyme

Panel Discussion: Creative Exit Strategies For Biotech Companies

    

Andrew Eibling, Manager, Alliance Management, Eli Lilly & Co.

Opening Panel Discussion: Proactive Approaches In Managing The Business Within Alliances

    

Jonathan Montagu, Director, Business Development, Concert Pharmaceuticals

Closing Panel Discussion: Continuing To Fund Your Portfolio In A Weak Financial Market

    

David Wurtman, Vice President, Business Development, NexBio

Therapeutic Area Partnering Primers-Infectious Disease

    

Sanj Singh, CEO, Ade Therapeutics

Global Partnering Roundtable Discussions -Canada, Canadian Research and Development Content Programs


    

Sanj Singh, CEO, Ade Therapeutics

Global Partnering Roundtable Discussions -Canada

    

Dr. Seth Rudnick, Venture Partner, Canaan Partners

Panel Discussion: Creative Exit Strategies For Biotech Companies

    

Beth Fordham-Meier, Senior Director, Business and Commercial Development, Targacept, Inc.

Opening Panel Discussion: Adding Value To A Deal – Utilizing Non Cash Assets Or Creatively Using Cash To Enhance Partnerships

    

Len Smith, Senior Intellectual Property Counsel, Novo Nordisk

Closing Discussion: Global Patent & Regulatory Strategies

    

Beth Fordham-Meier, Senior Director, Business and Commercial Development, Targacept

Therapeutic Area Partnering Primers-Central Nervous System